Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

All
Media Highlights
Press Releases
Media

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now
Media

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

July 24, 2026

Fierce Biotech

Read Now
Media

Eli Lilly-Backed Scribe Therapeutics Soars 44% After IPO

July 24, 2026

Bloomberg News

Read Now
Media

Scribe Bets on a New Era of Gene Editing

July 24, 2026

Bloomberg Tech

Read Now
Media

Scribe prices upsized IPO before producing human efficacy data

July 24, 2026

Axios

Read Now
Media

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

July 24, 2026

MedCity News

Read Now
Press release

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Read Now
Press release

Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences

September 9, 2025

Read Now
Press release

Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences

August 25, 2025

Read Now
Press release

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

Read Now
Press release

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division

May 5, 2025

Read Now
Press release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now

Publications